HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc. provides a novel technology platform that allows for precise, efficient molecular profiling of a wide variety of samples including formalin-fixed paraffin-embedded tissue. Our automated HTG Edge platform is designed to quickly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies.
The HTG Edge platform provides significant workflow and performance advantages in molecular profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. We developed our platform to facilitate the routine use of complex molecular profiling for molecular labs from research to the clinic.
The breakthroughs in genomic testing give the promise of an understanding of the unique biology of an individual patients cancer. Tumor profiling, which combines test results from techniques such as immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR) and next-generation sequencing (NGS), is becoming increasingly available to oncologists. The proliferation of these technologies, while exciting, presents several challenges to widespread adoption in the clinic. HTG Molecular Diagnostics, Inc. is focused on delivering on the promise of these tumor profiling breakthroughs through reduced usage of precious tissue specimens, platform consolidation, and optimization of testing efficiency.